Advertisement.

Nicholas Vardy

share

Global stock markets recovered last week with the Dow Jones up 1.29% and the S&P 500 rising 1.41%. The MCSI Emerging Markets Index jumped 1.50% Big gainers in your Bull Market Alert portfolio included biotech bets Novo Nordisk (NVO) and last week’s pick Medivation (MDVN), which ended the week up 4.81% and 3.80%, respectively. You […]

share

On Monday, I recommended that you bet again on biotech by buying Medivation, Inc. (MDVN).   Well, if you did, you’ve already made a quick 71.18% gain on your December $62.50 call options in the stock.   Today, I am recommending that you sell half of your options here to lock in your quick gains. […]

share

This week’s Dividend Pro recommendation expands your sources of high-yield income in the red-hot master limited partnership sector. You already own a master limited partnership (MLP) sector in the form of Vanguard Natural Resources (VNR), currently paying an impressive yield of 8.3%. This week’s Dividend Pro recommendation — UBS E-TRACS 2x Leveraged Long Alerian MLP Infrastructure Index ETN (MLPL) — is […]

share

Last week was a staid one for most global stock markets. The Dow Jones was up 0.18%, S&P 500 rose 0.29%, while the NASDAQ remained essentially flat. Emerging markets outperformed developed ones with the MCSI Emerging Markets Index ending the week 1.65% higher.   The big news in your portfolio was the buyout offer for […]

share

1.  The “Great Recession” in the United States Was Worse Than You Thought According to original estimates, U.S. gross domestic product (GDP) fell 3.8% for Q4 of 2008 — the quarter following the collapse of Lehman Brothers. Since then — in one of the most underreported stories ever — that number has been revised up to […]

share

Global stock markets continued their recent pullback last week. The Dow Jones was down 1.05% and the S&P 500 dropped 1.33%. The MCSI Emerging Markets Index (EEM) also fell back 1.08%   As a result, you were stopped out of both Standard Pacific Corp. (SPF) and ProShares Ultra NASDAQ Biotechnology (BIB), both at a gain. […]

X
Are YOU Ready for the Biden Disaster Plan?
"...It's worse than you think."
—Dr. Mark Skousen